Cargando…
Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer
The majority of ovarian cancer patients with advanced disease at diagnosis will relapse following primary treatment, with a dismal prognosis. Monitoring the levels of serum markers in patients under follow-up may be essential for the early detection of relapse, and for distinguishing high-risk patie...
Autores principales: | STEFFENSEN, KARINA DAHL, WALDSTRØM, MARIANNE, BRANDSLUND, IVAN, LUND, BENTE, SØRENSEN, SARAH MEJER, PETZOLD, MAX, JAKOBSEN, ANDERS |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888273/ https://www.ncbi.nlm.nih.gov/pubmed/27313725 http://dx.doi.org/10.3892/ol.2016.4533 |
Ejemplares similares
-
Immunohistochemical Expression of Platelet-Derived Growth Factor Receptors in Ovarian Cancer Patients with Long-Term Follow-Up
por: Madsen, Christine Vestergaard, et al.
Publicado: (2012) -
Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab
por: Madsen, Christine Vestergaard, et al.
Publicado: (2012) -
Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer
por: Steffensen, Karina Dahl, et al.
Publicado: (2010) -
Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy
por: Henriksen, Jon Røikjær, et al.
Publicado: (2020) -
Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer
por: Faaborg, Louise, et al.
Publicado: (2022)